search
Back to results

Dexmedetomidine and Propofol for Pediatric MRI Sedation

Primary Purpose

Headache, Tumor, Seizure Disorder

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
propofol
Dexmedetomidine
Glycopyrrolate
Lidocaine 1% Injectable Solution
Nitrous Oxide
Sevoflurane
Sponsored by
Medical College of Wisconsin
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Headache

Eligibility Criteria

12 Months - 60 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All children scheduled for outpatient MRI scans with expected duration of scan between 30 minutes and 75 minutes.

Exclusion Criteria:

  • Inpatient status, airway abnormalities, allergy to any study medications, eggs and soy, and mitochondrial disorders.
  • All subjects with any cardiac disease or history of cardiac arrhythmias will be excluded.

Sites / Locations

  • Children's Hospital of Wisconsin

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

propofol

propofol dexmedetomidine

Arm Description

Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.

Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.

Outcomes

Primary Outcome Measures

Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion
Time (minutes) from anesthesia start to readiness for discharge from the department to home or clinic.

Secondary Outcome Measures

Total Propofol Administered
total propofol administered (mg/kg)
Dexmedetomidine Dose
dexmedetomidine dose (mcg/kg)
Glycopyrrolate Dose
glycopyrrolate dose (mcg/kg)
Lidocaine Dose
lidocaine dose (mg/kg)
Nitrous Oxide
documentation of use
Sevoflurane
sevoflurane induction time of 5 minutes
Eye Opening
minutes from completion of scan to spontaneous eye opening
Oral/Enteral Intake
minutes from completion of scan to oral/enteral intake
Discharge Ready
minutes from completion of scan to discharge ready
Sleep Pattern
parental observation of deviation from child's normal habit obtained through follow-up phone call
Irritability
behavior deemed inappropriate and a deviation from child's normal though parental observation obtained through follow-up phone call
Delirium
Pediatric Anesthesia Emergence Delirium (PAED) score greater than 12 as defined by Sikich and Lerman. 0 = no delirium, 20 = worst possible delirium; 5 categories scored from 0-4 additive for a maximum score of 20. Categories 1-3 are scored the same and categories ar scored inversely as described. 1. Child makes contact with caregiver, 2. child's actions are purposeful, 3. child is aware of his surroundings. For each of these category, score 0 for extremely, 1 for very much, 2 for quite a bit, 3 for just a little, 4 for not at all. The other 2 categories 4. Child is restless and 5 Child is inconsolable are scored as 0 for not at all, 1 for just a little, 2 for quite a bit, 3 for very much, 4 for extremely

Full Information

First Posted
February 4, 2018
Last Updated
February 19, 2020
Sponsor
Medical College of Wisconsin
search

1. Study Identification

Unique Protocol Identification Number
NCT03513757
Brief Title
Dexmedetomidine and Propofol for Pediatric MRI Sedation
Official Title
An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
March 4, 2018 (Actual)
Primary Completion Date
August 21, 2018 (Actual)
Study Completion Date
October 21, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical College of Wisconsin

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia for MRI studies in young children (propofol). The drugs used for the MRI scan in this study will be chosen randomly. Half the patients will receive small doses of propofol and dexmedetomidine. The other half will receive propofol administered constantly throughout the scan. Other drugs that may be used include sevoflurane and nitrous oxide at the start of the sedation (for placing an intravenous), lidocaine (to reduce the pain of propofol injection) and glycopyrrolate (to prevent the heart rate from decreasing too low. The investigators will record 5 additional blood pressures and heart rates. If additional medications are required to complete the scan, the investigators will administer whatever is necessary. At the end of the study, the investigators will have an observer record the time it takes for participants to spontaneously open eyes , to be able to drink liquids and/or eat and to behave as before the study. Also, it is very important that the investigators find out from participants about changes in behavior, or if eating or sleeping habits were unusual following completion of the study. For that reason, the investigators will call participants in a day or so following the MRI scan. The investigators expect to recruit 40 children between the ages of 12 and 72 months for the study and hope to have the study completed in December 2018.
Detailed Description
The purpose of this study is to compare the results of combining two anesthetic medications (dexmedetomidine and propofol) in low doses with a standard dose of a single drug that is commonly used to provide sedation/anesthesia for MRI studies in young children (propofol). Recent studies and the FDA have raised concerns that anesthesia for longer than three hours may have effects on behavior and learning. Although investigators do not know if these effects are caused by drugs or the medical condition a child is being treated for, in December 2016, the FDA published the information below regarding anesthesia for children: General anesthetic and sedation drugs are used to put people into a deep sleep so they do not feel pain during surgery or procedures. These drugs are usually injected into a vein or breathed in through a mask. General anesthetic and sedation drugs are widely used to ensure the health, safety, and comfort of children and adults undergoing surgery or other procedures. Recent studies in children suggest that a single, relatively short exposure to general anesthetic and sedation drugs in infants or toddlers is unlikely to have negative effects on behavior or learning. More research is still needed to fully understand how anesthetics might affect brain development, especially longer or repeated exposures and in more vulnerable children. Anesthetic and sedation drugs are necessary for infants, children, and pregnant women who require surgery or other painful and stressful procedures. https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm Research in neonatal and infant animals has demonstrated that sedative and anesthetic agents, like propofol, produce adverse effects on brain development, including loss of brain cells resulting in long-term, possibly permanent changes in learning and behavior. These adverse effects appear to occur mostly after prolonged periods of sedation or anesthesia (generally greater than 3 hours) and when brain development is occurring at a rapid rate (which roughly occurs in children under 3 years of age). It is not known if similar adverse effects occur in humans. Study participants should be advised that the drugs used to accomplish the procedure may have the potential to increase the loss of nerve cells in the developing brain of young child and that the clinical significance of any such changes is not known. There are some animal studies that suggests dexmedetomidine may be better for a growing infant's brain. However, the effects of dexmedetomidine alone or in combination with propofol on the developing brain have not been thoroughly tested to date." The drugs used for the MRI scan in this study will be chosen randomly. Half the patients will receive small doses of propofol and dexmedetomidine. The other half will receive propofol administered constantly throughout the scan. Other drugs that may be used include sevoflurane and nitrous oxide at the start of the sedation (for placing an intravenous), lidocaine (to reduce the pain of propofol injection) and glycopyrrolate (to prevent the heart rate from decreasing too low. Investigators will record 5 additional blood pressures and heart rates. If additional medications are required to complete the scan, investigators will administer whatever is necessary. At the end of the study, an observer will record the time it takes for spontaneous eye opening, to be able to drink liquids and/or eat and to behave as before the study. Also, it is very important that investigators learn in the following day or two how the participant behaved at home; whether eating, behavior and sleeping were unusual. For that reason, the investigator will call the participant a day or so following the MRI scan. The investigators expect to recruit 70 children between the ages of 12 and 72 months for the study and hope to have the study completed in 2018.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
observer blinded comparison of propofol with low-dose propofol and dexmedetomidine for pediatric MRI sedation
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
The patients and their parents/guardians as well as the blinded observer or investigator who participates in outcomes assessment will be blinded to the drug or drugs administered.
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
propofol
Arm Type
Active Comparator
Arm Description
Each patient will receive 1 mg/kg lidocaine followed by 2 mg/kg propofol IV once prior to continuous propofol infusion for MRI sedation at 200 mcg/kg/min. Dose will be increased by 50 mcg/kg/min up to 300 mcg/kg/min for movement and decreased to 150 mcg/kg/min if no movement after 30 minutes. Additional 1 mg/kg propofol bolus administered at time of each movement. Study to be terminated if movement persists despite above interventions.
Arm Title
propofol dexmedetomidine
Arm Type
Experimental
Arm Description
Each patient will receive: 1 mg/kg lidocaine, 2 mg/kg propofol, 4 mcg/kg glycopyrrolate and single dose dexmedetomidine administered prior to scan. Dexmedetomidine dose is dependent on expected duration of scan and will be equal to 1 mcg/kg/hour x duration of scan in hours. 1 mg/kg propofol will be administered for movement up to 2 times. For continued movement after that, begin propofol infusion at 150 mcg/kg/min. Study to be terminated if movement persists despite above interventions.
Intervention Type
Drug
Intervention Name(s)
propofol
Other Intervention Name(s)
diprivan
Intervention Description
propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Other Intervention Name(s)
precedex
Intervention Description
single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
Intervention Type
Drug
Intervention Name(s)
Glycopyrrolate
Other Intervention Name(s)
Robinul
Intervention Description
4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
Intervention Type
Drug
Intervention Name(s)
Lidocaine 1% Injectable Solution
Other Intervention Name(s)
Xylocaine 1%
Intervention Description
1 mg/kg intravenous administration prior to propofol administration
Intervention Type
Drug
Intervention Name(s)
Nitrous Oxide
Intervention Description
Inhalation of nitrous oxide may be used for IV placement
Intervention Type
Drug
Intervention Name(s)
Sevoflurane
Other Intervention Name(s)
Ultane
Intervention Description
Inhalation of sevoflurane may be used for IV placement
Primary Outcome Measure Information:
Title
Efficiency of Propofol Dexmedetomidine Sedation Compared With Propofol Infusion
Description
Time (minutes) from anesthesia start to readiness for discharge from the department to home or clinic.
Time Frame
through study completion, an average of 2 hours
Secondary Outcome Measure Information:
Title
Total Propofol Administered
Description
total propofol administered (mg/kg)
Time Frame
up to 90 minutes
Title
Dexmedetomidine Dose
Description
dexmedetomidine dose (mcg/kg)
Time Frame
up to 90 minutes
Title
Glycopyrrolate Dose
Description
glycopyrrolate dose (mcg/kg)
Time Frame
5 minutes
Title
Lidocaine Dose
Description
lidocaine dose (mg/kg)
Time Frame
up to 90 minutes
Title
Nitrous Oxide
Description
documentation of use
Time Frame
up to 10 minutes
Title
Sevoflurane
Description
sevoflurane induction time of 5 minutes
Time Frame
sevoflurane induction time up to 10 minutes
Title
Eye Opening
Description
minutes from completion of scan to spontaneous eye opening
Time Frame
up to 90 minutes
Title
Oral/Enteral Intake
Description
minutes from completion of scan to oral/enteral intake
Time Frame
up to 2 hours
Title
Discharge Ready
Description
minutes from completion of scan to discharge ready
Time Frame
up to 2 hours
Title
Sleep Pattern
Description
parental observation of deviation from child's normal habit obtained through follow-up phone call
Time Frame
up to 48 hours
Title
Irritability
Description
behavior deemed inappropriate and a deviation from child's normal though parental observation obtained through follow-up phone call
Time Frame
up to 48 hours
Title
Delirium
Description
Pediatric Anesthesia Emergence Delirium (PAED) score greater than 12 as defined by Sikich and Lerman. 0 = no delirium, 20 = worst possible delirium; 5 categories scored from 0-4 additive for a maximum score of 20. Categories 1-3 are scored the same and categories ar scored inversely as described. 1. Child makes contact with caregiver, 2. child's actions are purposeful, 3. child is aware of his surroundings. For each of these category, score 0 for extremely, 1 for very much, 2 for quite a bit, 3 for just a little, 4 for not at all. The other 2 categories 4. Child is restless and 5 Child is inconsolable are scored as 0 for not at all, 1 for just a little, 2 for quite a bit, 3 for very much, 4 for extremely
Time Frame
up to 24 hours.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Months
Maximum Age & Unit of Time
60 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All children scheduled for outpatient MRI scans with expected duration of scan between 30 minutes and 75 minutes. Exclusion Criteria: Inpatient status, airway abnormalities, allergy to any study medications, eggs and soy, and mitochondrial disorders. All subjects with any cardiac disease or history of cardiac arrhythmias will be excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan P Taylor, MD, MPH
Organizational Affiliation
Children's Hospital and Health System Foundation, Wisconsin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
28177852
Citation
Andropoulos DB, Greene MF. Anesthesia and Developing Brains - Implications of the FDA Warning. N Engl J Med. 2017 Mar 9;376(10):905-907. doi: 10.1056/NEJMp1700196. Epub 2017 Feb 8. No abstract available.
Results Reference
background
PubMed Identifier
18055659
Citation
Vespasiano M, Finkelstein M, Kurachek S. Propofol sedation: intensivists' experience with 7304 cases in a children's hospital. Pediatrics. 2007 Dec;120(6):e1411-7. doi: 10.1542/peds.2007-0145.
Results Reference
background
PubMed Identifier
24859263
Citation
Emrath ET, Stockwell JA, McCracken CE, Simon HK, Kamat PP. Provision of deep procedural sedation by a pediatric sedation team at a freestanding imaging center. Pediatr Radiol. 2014 Aug;44(8):1020-5. doi: 10.1007/s00247-014-2942-z. Epub 2014 May 24.
Results Reference
background
PubMed Identifier
19645979
Citation
Mallory MD, Baxter AL, Kost SI; Pediatric Sedation Research Consortium. Propofol vs pentobarbital for sedation of children undergoing magnetic resonance imaging: results from the Pediatric Sedation Research Consortium. Paediatr Anaesth. 2009 Jun;19(6):601-11. doi: 10.1111/j.1460-9592.2009.03023.x.
Results Reference
background
PubMed Identifier
18363626
Citation
Mason KP, Zurakowski D, Zgleszewski SE, Robson CD, Carrier M, Hickey PR, Dinardo JA. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth. 2008 May;18(5):403-11. doi: 10.1111/j.1460-9592.2008.02468.x. Epub 2008 Mar 18.
Results Reference
background
PubMed Identifier
21210884
Citation
Siddappa R, Riggins J, Kariyanna S, Calkins P, Rotta AT. High-dose dexmedetomidine sedation for pediatric MRI. Paediatr Anaesth. 2011 Feb;21(2):153-8. doi: 10.1111/j.1460-9592.2010.03502.x.
Results Reference
background
PubMed Identifier
27872485
Citation
Akpinar H, Naziroglu M, Ovey IS, Cig B, Akpinar O. The neuroprotective action of dexmedetomidine on apoptosis, calcium entry and oxidative stress in cerebral ischemia-induced rats: Contribution of TRPM2 and TRPV1 channels. Sci Rep. 2016 Nov 22;6:37196. doi: 10.1038/srep37196. Erratum In: Sci Rep. 2018 Jul 04;8:47002.
Results Reference
background
PubMed Identifier
27779360
Citation
Boriosi JP, Eickhoff JC, Klein KB, Hollman GA. A retrospective comparison of propofol alone to propofol in combination with dexmedetomidine for pediatric 3T MRI sedation. Paediatr Anaesth. 2017 Jan;27(1):52-59. doi: 10.1111/pan.13041. Epub 2016 Oct 25.
Results Reference
background
PubMed Identifier
15114210
Citation
Sikich N, Lerman J. Development and psychometric evaluation of the pediatric anesthesia emergence delirium scale. Anesthesiology. 2004 May;100(5):1138-45. doi: 10.1097/00000542-200405000-00015.
Results Reference
background

Learn more about this trial

Dexmedetomidine and Propofol for Pediatric MRI Sedation

We'll reach out to this number within 24 hrs